-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Immuno-co-culture killing model platform by InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-08-21
In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.
Background and Establishment of the Platform
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University. Since its establishment, the company has been focusing on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services and individualized medicine, and is committed to providing a new generation of experimental animal models close to the clinic. Its immune co-culture killing model platform is an important technological breakthrough in this direction.
Platform Features and Technical Advantages
1. Precise cell culture technology
Through advanced cell culture technology, the immune co-culture killing model constructs a more realistic three-dimensional tissue structure, simulating the complex interaction between immune cells and tumor cells in the body. This model not only improves the biological realism of experiments, but also enables researchers to more accurately predict the effects of therapeutic drugs in the body.
2. Introduction of multiple cell types
Unlike traditional immune models, this model is able to introduce multiple immune cell types at the same time, such as natural killer cells (NK cells) and T cells. The introduction of multiple cell types makes the simulated immune response process more complex and closer to the real situation, and the experimental results are more biologically meaningful.
3. Advanced Microscopy and Imaging Analysis
The platform uses advanced microscopy technology and imaging analysis to provide real-time observation at the cellular level. This visualization feature enables researchers to intuitively observe the killing process of immune cells and gain a deeper understanding of the mechanism of immunotherapy.
4. Exhaustive biomarker analysis
The model allows detailed analysis of biomarkers in the immune response, helping researchers to discover potential predictive indicators that provide an important basis for clinical research and the design of therapeutic regimens.

Application Areas and Impact
1. Cancer therapeutic research
The immune co-culture killing model has a wide range of applications in cancer therapy research. It can efficiently and accurately assess the immuno-killing effect of potential therapeutic drugs, optimize the engineering of immune cells, and improve their recognition and killing ability of tumor cells. In addition, based on a patient's immune profile, the platform can customize treatment plans and improve the individualization of treatment.
2. Drug Screening and Evaluation
The platform can be used for large-scale drug screening to assess the killing effect and toxicity level of drugs on cells, providing important data for safety assessment during drug development. This efficient screening mechanism helps to shorten the cycle of new drug development and reduce R&D costs.
3. Translational Medicine and Individualized Medicine
InnoModels' immune co-culture killing model platform also promotes the development of translational medicine and individualized medicine. By providing an experimental platform that is closer to the actual clinical situation, researchers are able to understand the disease mechanism and therapeutic effects more deeply, providing more accurate guidance for clinical diagnosis and treatment.
Conclusion
The launch of InnoModels' immune co-culture killing model platform marks an important leap in immunotherapy research. With its precise technology, wide range of applications and far-reaching impact, the platform provides a solid scientific foundation for research on cancer treatment and immunotherapy. In the future, with the continuous advancement of technology and in-depth expansion of applications, InnoModels Biotechnology will continue to play an important role in life science and pharmaceutical R&D, bringing more hope and possibilities to patients.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd